The diagnostic utility of cerebrospinal fluid alpha-synuclein analysis in dementia with Lewy bodies - A systematic review and meta-analysis

Parkinsonism and Related Disorders

Volumn 19, Issue 10, 2013, Pages 851-858

  Lim, Xuxin ^a   Yeo, Jing Ming ^a   Green, Alison ^b   Pal, Suvankar ^b,c,d  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b WESTERN GENERAL HOSPITAL   (United Kingdom)

^c FORTH VALLEY ROYAL HOSPITAL   (United Kingdom)

^d UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

Alpha synuclein; Biomarker; Cerebrospinal fluid; Dementia; Dementia with Lewy bodies

Indexed keywords

ALPHA SYNUCLEIN;

ALZHEIMER DISEASE; CEREBROSPINAL FLUID ANALYSIS; DATA BASE; DEGENERATIVE DISEASE; DEMENTIA; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; DIFFUSE LEWY BODY DISEASE; HUMAN; INFORMATION RETRIEVAL; META ANALYSIS (TOPIC); PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW; STATISTICAL MODEL; STUDY DESIGN; SYSTEMATIC REVIEW;

ALPHA-SYNUCLEIN; BIOMARKER; CEREBROSPINAL FLUID; DEMENTIA; DEMENTIA WITH LEWY BODIES;

ADULT; AGE OF ONSET; AGED; AGED, 80 AND OVER; ALPHA-SYNUCLEIN; ALZHEIMER DISEASE; DATA INTERPRETATION, STATISTICAL; FEMALE; HUMANS; LEWY BODY DISEASE; MALE; MIDDLE AGED; NEURODEGENERATIVE DISEASES; NEUROPSYCHOLOGICAL TESTS; PUBLICATION BIAS; REPRODUCIBILITY OF RESULTS; RESEARCH DESIGN; YOUNG ADULT;

EID: 84883263721     PISSN: 13538020     EISSN: 18735126     Source Type: Journal    
DOI: 10.1016/j.parkreldis.2013.06.008     Document Type: Review

References (26)

1. McKeith I. Dementia with Lewy bodies. Dialog Clin Neurosci 2004, 6(3):333-341.
2. Zaccai J., McCracken C., Brayne C. Asystematic review of prevalence and incidence studies of dementia with Lewy bodies. Age Ageing 2005, 34(6):561-566.
3. Marti M.J., Tolosa E., Campdelacreu J. Clinical overview of the synucleinopathies. Mov Disord 2003, 18(Suppl.6):S21-S27.
4. McKeith I., Mintzer J., Aarsland D., Burn D., Chiu H., Cohen-Mansfield J., et al. International Psychogeriatric Association Expert Meeting on DLB: dementia with Lewy bodies. Lancet Neurol 2004, 3:19-28.
5. Wennstrom M., Surova Y., Hall S., Nilsson C., Minthon L., Bostrom F., et al. Low CSF levels of both alpha-synuclein and the alpha-synuclein cleaving enzyme neurosin in patients with synucleinopathy. PLoS ONE 2013, 8(1):e53250.
6. McKeith I., Dickson D., Lowe J., Emre M., O'Brien J., Feldman H., et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB consortium. Neurology 2005, 65(12):1863-1872.
7. McKeith I., Galasko D., Kosaka K., Perry E., Dickson D., Hansen L., et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 1996, 47(5):1113-1124.
8. McKeith I., O'Brien J.T., Ballard C. Diagnosing dementia with Lewy bodies. Lancet 2003, 354(9186):1227-1228.
9. Mckeith I. Dementia with Lewy bodies and Parkinson. Parkinsonism 2004, 10:S15-S18.
10. McKhann G.M., Drachman D., Folstein M., Katzman R., Price D., Stadlan E.M. Clinical diagnosis of Alzheimers disease: a report of the NINCDS-ADRDA work group. Neurology 1984, 34:934-942.
11. Hughes A. UK Parkinson's disease society brain bank clinical diagnostic criteria. JNeurol 1992, 55:1992.
12. The Lund and Manchester Groups Statement C. Clinical and neuropathological criteria for fronto-temporal dementia. JNeurol, Neurosurg Psychiatry 1994, 57(4):416-418.
13. Tateno F., Sakakibara R., Kawai Takayuki, Kishi M., Murano T. Alpha-synuclein in the cerebrospinal fluid differentiates synucleinopathies (Parkinson's disease, dementia with Lewy body, multiple system atrophy) from Alzheimer disease. Alzheimer Dis Assoc Disord 2012, 26(3):213-216.
14. Mollenhauer B., Locascio J.J., Schulz-Schaeffer W., Sixel-Doring F., Trenkwalder C., Schlossmacher M.G. alpha-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study. Lancet Neurol 2011, 10(3):230-240.
15. Parnetti L., Chiasserini D., Bellomo G., Giannandrea D., De Carlo C., Qureshi M.M., et al. Cerebrospinal fluid Tau/alpha-synuclein ratio in Parkinson's disease and degenerative dementias. Mov Disord 2011, 26(8):1428-1435.
16. Spies P.E., Melis R.J., Sjogren M.J., Rikkert M.G., Verbeek M.M. Cerebrospinal fluid alpha-synuclein does not discriminate between dementia disorders. JAlzheimers Dis 2009, 16(2):363-369.
17. Kasuga K., Tokutake T., Ishikawa A., Uchiyama T., Tokuda T., Onodera O., et al. Differential levels of alpha-synuclein, beta amyloid 42 and tau in CSF between patients with dementia with Lewy bodies and Alzheimer's disease. JNeurol Neurosurg Psychiatry 2010, 81(6):608-610.
18. Mollenhauer B., Cullen V., Kahn I., Krastins B., Outeiro T.F., Pepivani I., et al. Direct quantification of CSF alpha-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration. Exp Neurol 2008, 213(2):315-325.
19. Noguchi-Shinohara M., Tokuda T., Yoshita M., Kasai T., Ono K., Nakagawa M., et al. CSF alpha-synuclein levels in dementia with Lewy bodies and Alzheimer's disease. Brain Res 2009, 1251:1-6.
20. Ohrfelt A., Grognet P., Andreasen N., Wallin A., Vanmechelen E., Blennow K., et al. Cerebrospinal fluid alpha-synuclein in neurodegenerative disorders - a marker of synapse loss?. Neurosci Lett 2009, 450:332-335.
21. Reesink F.E., Lemstra A.W., van Dijk K.D., Berendse H.W., van de Berg W.D., Klein M., et al. CSF alpha-synuclein does not discriminate dementia with Lewy bodies from Alzheimer's disease. JAlzheimers Dis 2010, 22(1):87-95.
22. Aerts M.B., Esselink R.A., Abdo W.F., Bloem B.R., Verbeek M.M. CSF alpha-synuclein does not differentiate between parkinsonian disorders. Neurobiol Aging 2012, 33(2):430e1-430e3.
23. Wennstrom M., Londos E., Minthon L., Nielsen H. CSF levels of orexin and a-synuclein are linked in DLB patients and elderly controls. JAlzheimers Dis 2012, 29(1):125-132.
24. Hall S., Ohrfelt A., Constantinescu R., Andreasson U., Surova Y., Bostrom F., et al. Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian disorders. Arch Neurol 2012 Nov, 69(11):1445-1452.
25. Del Campo M., Mollenhauer B., Bertolotto A., Engelborghs S., Hampel H., Simonsen A.H., et al. Recommendations to standardize preanalytical confounding factors in Alzheimers and Parkinsons disease cerebrospinal fluid biomarkers: an update. Biomark Med 2012, 6(4):419-430.
26. Beyer K. Alpha-synuclein structure, posttranslational modification and alternative splicing as aggregation enhancers. Acta Neuropathol 2006, 112(3):237-251.